Editor’s note: This story has been corrected to state that Castellum Inc — not Constellium SE — announced the pricing of a public stock offering.
With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
- Viracta Therapeutics, Inc. VIRX said its board has initiated a process to explore a broad range of strategic alternatives. The company announced plans to close its ongoing pivotal Phase 2 clinical trial of Nana-val in Relapsed/Refractory EBV + Lymphomas. Viracta Therapeutics shares dipped 13.9% to $0.2040 in the after-hours trading session.
- Evaxion Biotech A/S EVAX applied for a patent for vaccines targeting Neisseria gonorrhoeae. Evaxion Biotech shares jumped 104.5% to $1.73 in after-hours trading.
- Castellum Inc CTM announced the pricing of a previously announced stock offering of 4,355,000 shares at 85 cents per share for gross proceeds of approximately $3.7 million.
Check out our premarket coverage here.
- Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
- Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
- Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.
- The Arena Group Holdings, Inc. AREN disclosed that its compliance plan was accepted by the NYSE American. Arena Group shares jumped 17.6% to $1.67 in the after-hours trading session.
- Grid Dynamics Holdings, Inc. GDYN will replace Revelyst Inc. GEAR in the S&P SmallCap 600 effective before the opening bell on Thursday, Jan. 2. Grid Dynamics shares jumped 9.7% to $23.11 in after-hours trading.
Photo courtesy: Wikimedia
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.